logo-loader
viewBiocept Inc

Biocept's validation testing of Target Selector for cancer mutations published in peer-review journal

The article in the journal PLOS ONE will be included as part of a special collection of topical articles entitled Targeted Anticancer Therapies And Precision Medicine In Cancer

Biocept Inc - Biocept Inc says peer-review journal published validation results showing the high sensitivity of its Target Selector testing for EGFR, BRAF and KRAS mutations in plasma circulating tumor DNA
Biocept is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma

Biocept Inc (NASDAQ:BIOC), a liquid biopsy provider, announced Monday that a peer-review journal published validation results showing the high sensitivity of its Target Selector testing for EGFR, BRAF and KRAS mutations in plasma circulating tumor DNA (ctDNA). 

The company said the article was published in the journal PLOS ONE this month and will also be included as part of a special collection of topical articles entitled Targeted Anticancer Therapies And Precision Medicine In Cancer.

In a statement, Biocept said Target Selector testing for EGFR, BRAF, and KRAS mutations has been validated to an ultra-sensitive single copy level, with a limit of detection (LOD) of 0.02% or better.

READ: Biocept wins South Korea patent for its Switch-Block technology used to detect rare cancer mutations

The San Diego-based company’s biomarker tests provide coverage for the most common actionable mutations associated with clinical guidelines for targeted cancer therapy.

Target Selector tests performed in Biocept's laboratory provide a commercial turnaround time of 3-4 days, and offer a cost-effective strategy to guide treatment decisions and monitor therapeutic response.  At the core of Target Selector is the company’s Switch-Blocker technology, used in detecting rare cancers associated with mutations.

"Biocept's patented Switch-Blocker technology uniquely amplifies mutations of interest from the blood of patients with cancer, while blocking wild type DNA. This enables very high sensitivity and detection down to a single gene copy," said Jason Poole, Biocept's vice president of research and development and the study's lead author.

"We are very pleased to have this analytical validation published in PLOS ONE, and believe the results demonstrate the high sensitivity and performance of our novel liquid biopsy assays, which are designed to provide oncologists with the information they need to select the right targeted therapy for their patients."

CEO Michael Nall noted that Target Selector liquid biopsies “continues to emerge as an important tool to cost-effectively qualify patients for therapy and, importantly, monitor therapeutic response and disease progression for physicians and their patients with cancer." 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 0.7662 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $17.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Biocept making great strides with its Switch-Blocker technology

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive that a peer-review journal named PLOS ONE has published validation results showing a higher sensitivity of the San Diego-based liquid biopsy provider's Target Selector, including its Switch-Blocker technology, which tests for rare cancers...

1 week, 5 days ago

2 min read